Norma Cavazos-Rocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Norma Cavazos-Rocha has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Lucio Vera-Cabrera
Laboratorio Interdisciplinario de Investigación Dermatológica, Servicio de Dermatología, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
6 shared publications Jorge Ocampo-Candiani
Laboratorio Interdisciplinario de Investigación Dermatológica, Servicio de Dermatología, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Nuevo León, México
5 shared publicationsOliverio Welsh
Servicio de Dermatología, Hospital Universitario José E. González, Monterrey, NL,1 Departamento de Química Analítica, Facultad de Medicina, UANL, Monterrey, NL,2 Centro de Investigación Biomédica del Noreste, IMSS, Monterrey, NL, México3
4 shared publications- Salvador Said-Fernández
Centro de Investigación del IPN
4 shared publications Hector Gerardo Lozano-Garza
Centro de Investigación Biomédica del Noreste, IMSS, Monterrey, Nuevo León, México
3 shared publicationsAlejandra Daw-Garza
Servicio de Dermatología, Hospital Universitario “José E. González”, Monterrey, Nuevo León, México
2 shared publications
Latest Publications
- Open Access
- 11 April 2022
- Published by Sociedad Quimica de Mexico, A.C. in Journal of the Mexican Chemical Society
- Vol. 66 (2) , 198-220
Fabrication and Characterization of a Laboratory–Made New Coating Based on 1-Decyl-3-Methylimidazolium Tetrafluoroborate for SPME Fibers, an Exploration to its Application in Extractions by Direct-Immersion Mode
A novel coating for solid-phase microextraction (SPME) fibers was manufactured by using a mixture of 1-decyl-3methylimidazolium tetrafluoroborate ionic liquid and a commercial adhesive deposited on an etched stainless-steel support. The new coating was characterized by applying optical and electron microscopy, infrared spectroscopy and its extraction capacity was also evaluated. The extraction capacity was tested using as model analytes some pharmaceutical and personal care products (PPCPs) with different hydrophilicities. The potential use of the new fiber was evaluated through direct-immersion mode extractions and showed extraction capacity toward methylparaben, propylparaben, naproxen, diclofenac and benzophenone-3. Experimental design tools were used to study and optimize the variables that affect the extraction and desorption processes of the SPME by direct immersion. The analytical performance of proposed method was investigated under SPME procedure´s optimal conditions, coupled to a high-performance liquid chromatography-diode array detector (HPLC-DAD) method, which was developed and validated for analysis of the target PPCPs. The method of SPME by direct immersion was linear, precise and accurate. Detection and quantification limits of 0.023 to 0.093 μg mL-1 and 0.118 to 0.279 μg mL-1 were obtained, respectively. By the use of the developed method, tap water samples were analyzed and recoveries from 3.39 to 183.29 % were found. The new fiber presented an adequate stability and good extraction reproducibility (<15 % RSD). As a final point, this device is of easy and quick preparation, inexpensive, and suitable for extraction of some PPCPs. Resumen. Se fabricó un nuevo recubrimiento para fibras de microextracción en fase sólida (SPME) utilizando una mezcla del líquido iónico tetrafluoroborato de 1-decil-3metilimidazolio y un adhesivo comercial depositada sobre un soporte de acero inoxidable grabado. El nuevo recubrimiento se caracterizó mediante la aplicación de microscopía óptica y electrónica, espectroscopía de infrarrojo y también se evaluó su capacidad de extracción. La capacidad de extracción se probó utilizando como analitos modelo algunos productos farmacéuticos y de cuidado personal (PPCPs) con diferentes hidrofilicidades. El uso potencial de la nueva fibra se evaluó mediante extracciones en modo de inmersión directa y mostró capacidad de extracción hacia metilparabeno, propilparabeno, naproxeno, diclofenaco y benzofenona-3. Se utilizaron herramientas del diseño experimental para estudiar y optimizar las variables que afectan los procesos de extracción y desorción de la SPME por inmersión directa. El rendimiento analítico del método propuesto se investigó en las condiciones óptimas del procedimiento de SPME, acoplado a un método de cromatografía líquida de alto rendimiento con detector de arreglo de diodos (HPLC-DAD), que fue desarrollado y validado para el análisis de los PPCPs objetivo. El método de SPME por inmersión directa fue lineal, preciso y exacto. Se obtuvieron límites de detección y cuantificación de 0.023 a 0.093 μg mL-1 y 0.118 a 0.279 μg mL-1, respectivamente. Mediante el uso del método desarrollado, se analizaron muestras de agua del grifo y se encontraron recuperaciones de 3.39 a 183.29 %. La nueva fibra presentó una adecuada estabilidad y buena reproducibilidad de extracción (<15 % RSD). Como punto final, este dispositivo es de fácil y rápida preparación, económico y adecuado para la extracción de algunos PPCPs.
- 11 April 2022
- Published by Sociedad Quimica de Mexico, A.C. in Journal of the Mexican Chemical Society
- Vol. 66 (2) , 198-220
Open AccessFabrication and Characterization of a Laboratory–Made New Coating Based on 1-Decyl-3-Methylimidazolium Tetrafluoroborate for SPME Fibers, an Exploration to its Application in Extractions by Direct-Immersion Mode
A novel coating for solid-phase microextraction (SPME) fibers was manufactured by using a mixture of 1-decyl-3methylimidazolium tetrafluoroborate ionic liquid and a commercial adhesive deposited on an etched stainless-steel support. The new coating was characterized by applying optical and electron microscopy, infrared spectroscopy and its extraction capacity was also evaluated. The extraction capacity was tested using as model analytes some pharmaceutical and personal care products (PPCPs) with different hydrophilicities. The potential use of the new fiber was evaluated through direct-immersion mode extractions and showed extraction capacity toward methylparaben, propylparaben, naproxen, diclofenac and benzophenone-3. Experimental design tools were used to study and optimize the variables that affect the extraction and desorption processes of the SPME by direct immersion. The analytical performance of proposed method was investigated under SPME procedure´s optimal conditions, coupled to a high-performance liquid chromatography-diode array detector (HPLC-DAD) method, which was developed and validated for analysis of the target PPCPs. The method of SPME by direct immersion was linear, precise and accurate. Detection and quantification limits of 0.023 to 0.093 μg mL-1 and 0.118 to 0.279 μg mL-1 were obtained, respectively. By the use of the developed method, tap water samples were analyzed and recoveries from 3.39 to 183.29 % were found. The new fiber presented an adequate stability and good extraction reproducibility (<15 % RSD). As a final point, this device is of easy and quick preparation, inexpensive, and suitable for extraction of some PPCPs. Resumen. Se fabricó un nuevo recubrimiento para fibras de microextracción en fase sólida (SPME) utilizando una mezcla del líquido iónico tetrafluoroborato de 1-decil-3metilimidazolio y un adhesivo comercial depositada sobre un soporte de acero inoxidable grabado. El nuevo recubrimiento se caracterizó mediante la aplicación de microscopía óptica y electrónica, espectroscopía de infrarrojo y también se evaluó su capacidad de extracción. La capacidad de extracción se probó utilizando como analitos modelo algunos productos farmacéuticos y de cuidado personal (PPCPs) con diferentes hidrofilicidades. El uso potencial de la nueva fibra se evaluó mediante extracciones en modo de inmersión directa y mostró capacidad de extracción hacia metilparabeno, propilparabeno, naproxeno, diclofenaco y benzofenona-3. Se utilizaron herramientas del diseño experimental para estudiar y optimizar las variables que afectan los procesos de extracción y desorción de la SPME por inmersión directa. El rendimiento analítico del método propuesto se investigó en las condiciones óptimas del procedimiento de SPME, acoplado a un método de cromatografía líquida de alto rendimiento con detector de arreglo de diodos (HPLC-DAD), que fue desarrollado y validado para el análisis de los PPCPs objetivo. El método de SPME por inmersión directa fue lineal, preciso y exacto. Se obtuvieron límites de detección y cuantificación de 0.023 a 0.093 μg mL-1 y 0.118 a 0.279 μg mL-1, respectivamente. Mediante el uso del método desarrollado, se analizaron muestras de agua del grifo y se encontraron recuperaciones de 3.39 a 183.29 %. La nueva fibra presentó una adecuada estabilidad y buena reproducibilidad de extracción (<15 % RSD). Como punto final, este dispositivo es de fácil y rápida preparación, económico y adecuado para la extracción de algunos PPCPs.
- 28 August 2019
- Published by Springer Nature in Water, Air, & Soil Pollution
- Vol. 230 (9) , 219
Determination of the Kinetic Behavior of Diclofenac in Aqueous Solution by UV Light Radiation
- 28 August 2019
- Published by Springer Nature in Water, Air, & Soil Pollution
- Vol. 230 (9) , 219
Determination of the Kinetic Behavior of Diclofenac in Aqueous Solution by UV Light Radiation
- 1 June 2019
- Published by Elsevier in Journal of Food Composition and Analysis
- Vol. 79, 134-142
A validated NMR method for the quantitative determination of rebaudioside A in commercial sweeteners
- 1 June 2019
- Published by Elsevier in Journal of Food Composition and Analysis
- Vol. 79, 134-142
A validated NMR method for the quantitative determination of rebaudioside A in commercial sweeteners
- Open Access
- 16 March 2018
- Published by Walter de Gruyter GmbH in Reviews in Analytical Chemistry
- Vol. 37 (2)
Developments of solid-phase microextraction fiber coatings for environmental pharmaceutical and personal care products analysis
Solid-phase microextraction (SPME) is a sample preparation technique with many applications that is being continuously developed. In this technique, the type of fiber coating plays a crucial role for extraction efficiency. Currently available commercial coatings have certain drawbacks that have been overcome by the development of new coatings based on novel materials; these have improved the efficiency of extraction, selectivity and stability of commercial coatings. Pharmaceutical and personal care products (PPCPs) are one of the most important groups of emerging contaminants; however, some studies suggest that these compounds can cause adverse health effects. No official monitoring protocols for these compounds are currently available, so the establishment of analytical methods that allow their determination in environmental samples is required. The complexity of environmental samples together with the low concentration levels of these compounds makes necessary the use of sample preparation techniques capable of removing interferences, as well as preconcentrated analytes, and SPME is a very promising alternative to achieve this. This review describes the recent developments in SPME with classical and novel coatings and its applications for PPCP determination in environmental samples.
- 16 March 2018
- Published by Walter de Gruyter GmbH in Reviews in Analytical Chemistry
- Vol. 37 (2)
Open AccessDevelopments of solid-phase microextraction fiber coatings for environmental pharmaceutical and personal care products analysis
Solid-phase microextraction (SPME) is a sample preparation technique with many applications that is being continuously developed. In this technique, the type of fiber coating plays a crucial role for extraction efficiency. Currently available commercial coatings have certain drawbacks that have been overcome by the development of new coatings based on novel materials; these have improved the efficiency of extraction, selectivity and stability of commercial coatings. Pharmaceutical and personal care products (PPCPs) are one of the most important groups of emerging contaminants; however, some studies suggest that these compounds can cause adverse health effects. No official monitoring protocols for these compounds are currently available, so the establishment of analytical methods that allow their determination in environmental samples is required. The complexity of environmental samples together with the low concentration levels of these compounds makes necessary the use of sample preparation techniques capable of removing interferences, as well as preconcentrated analytes, and SPME is a very promising alternative to achieve this. This review describes the recent developments in SPME with classical and novel coatings and its applications for PPCP determination in environmental samples.
- Open Access
- 16 October 2015
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (10) , e0004022
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis
Mycetoma is a neglected, chronic, and deforming infectious disease caused by fungi and actinomycetes. In Mexico, N. brasiliensis is the predominant etiologic agent. Therapeutic alternatives are necessary because the current drug regimens have several disadvantages. Benzothiazinones (BTZ) are a new class of candidate drugs that inhibit decaprenyl-phosphoribose-epimerase (DprE1), an essential enzyme involved in the cell wall biosynthesis of Corynebacterineae. In this study, the in vitro activity of the next generation BTZ, PBTZ169, was tested against thirty Nocardia brasiliensis isolates. The MIC50 and MIC90 values for PBTZ169 were 0.0075 and 0.03 μg/mL, respectively. Because Nocardia is a potential intracellular bacterium, a THP-1 macrophage monolayer was infected with N. brasiliensis HUJEG-1 and then treated with PBTZ169, resulting in a decrease in the number of colony-forming units (CFUs) at a concentration of 0.25X the in vitro value. The in vivo activity was evaluated after infecting female BALB/c mice in the right hind food-pad. After 6 weeks, treatment was initiated with PBTZ169 and its activity was compared with the first generation compound, BTZ043. Both BTZ compounds were administered at 100 mg/kg twice daily by gavage, and sulfamethoxazole/trimethoprim (SXT), at 100 mg/kg sulfamethoxazole, was used as a positive control. After 22 weeks of therapy, only PBTZ169 and SXT displayed statistically significant activity. These results indicate that DprE1 inhibitors may be useful for treating infections of Nocardia and may therefore be active against other actinomycetoma agents. We must test combinations of these compounds with other antimicrobial agents, such as linezolid, tedizolid or SXT, that have good to excellent in vivo activity, as well as new DprE1 inhibitors that can achieve higher plasma levels. Mycetoma is a neglected tropical disease caused by many etiological agents, including actinobacteria and true fungi. In Mexico, Nocardia brasiliensis and Actinomadura madurae account for more than 90% of the total cases. This subcutaneous infectious disease can affect skin and subcutaneous tissue; actinomycetomas are particularly osteolytic. The presence of abundant scar tissue, pus, and the intracellular growth of Nocardia make treatment very difficult. Current N. brasiliensis actinomycetoma therapy includes the use of trimethoprim-sulamethozaxole, diamino-diphenyl-sulphone (DDS), amikacin, and amoxicillin-clavulanate. N. brasiliensis is resistant to many other antimicrobials due in part to its richness in copies of genes related to pharmacoresistance, for instance rpoB, gyrase, beta-lactams, P450 cytochromes, etc. DprE1 inhibitors are new types of compounds that target a completely different gene, dprE1, encoding the decaprenylphosphoryl-d-ribose oxidase. Assays evaluating these experimental or other new drugs are necessary to develop a better therapeutic scheme for actinomycetoma, with more potent, less toxic antimicrobials.
- 16 October 2015
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (10) , e0004022
Open AccessIn Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis
Mycetoma is a neglected, chronic, and deforming infectious disease caused by fungi and actinomycetes. In Mexico, N. brasiliensis is the predominant etiologic agent. Therapeutic alternatives are necessary because the current drug regimens have several disadvantages. Benzothiazinones (BTZ) are a new class of candidate drugs that inhibit decaprenyl-phosphoribose-epimerase (DprE1), an essential enzyme involved in the cell wall biosynthesis of Corynebacterineae. In this study, the in vitro activity of the next generation BTZ, PBTZ169, was tested against thirty Nocardia brasiliensis isolates. The MIC50 and MIC90 values for PBTZ169 were 0.0075 and 0.03 μg/mL, respectively. Because Nocardia is a potential intracellular bacterium, a THP-1 macrophage monolayer was infected with N. brasiliensis HUJEG-1 and then treated with PBTZ169, resulting in a decrease in the number of colony-forming units (CFUs) at a concentration of 0.25X the in vitro value. The in vivo activity was evaluated after infecting female BALB/c mice in the right hind food-pad. After 6 weeks, treatment was initiated with PBTZ169 and its activity was compared with the first generation compound, BTZ043. Both BTZ compounds were administered at 100 mg/kg twice daily by gavage, and sulfamethoxazole/trimethoprim (SXT), at 100 mg/kg sulfamethoxazole, was used as a positive control. After 22 weeks of therapy, only PBTZ169 and SXT displayed statistically significant activity. These results indicate that DprE1 inhibitors may be useful for treating infections of Nocardia and may therefore be active against other actinomycetoma agents. We must test combinations of these compounds with other antimicrobial agents, such as linezolid, tedizolid or SXT, that have good to excellent in vivo activity, as well as new DprE1 inhibitors that can achieve higher plasma levels. Mycetoma is a neglected tropical disease caused by many etiological agents, including actinobacteria and true fungi. In Mexico, Nocardia brasiliensis and Actinomadura madurae account for more than 90% of the total cases. This subcutaneous infectious disease can affect skin and subcutaneous tissue; actinomycetomas are particularly osteolytic. The presence of abundant scar tissue, pus, and the intracellular growth of Nocardia make treatment very difficult. Current N. brasiliensis actinomycetoma therapy includes the use of trimethoprim-sulamethozaxole, diamino-diphenyl-sulphone (DDS), amikacin, and amoxicillin-clavulanate. N. brasiliensis is resistant to many other antimicrobials due in part to its richness in copies of genes related to pharmacoresistance, for instance rpoB, gyrase, beta-lactams, P450 cytochromes, etc. DprE1 inhibitors are new types of compounds that target a completely different gene, dprE1, encoding the decaprenylphosphoryl-d-ribose oxidase. Assays evaluating these experimental or other new drugs are necessary to develop a better therapeutic scheme for actinomycetoma, with more potent, less toxic antimicrobials.
- Open Access
- 3 March 2014
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 52 (10) , 1281-1287
HPLC Method for the Simultaneous Analysis of Fluoroquinolones and Oxazolidinones in Plasma
A chromatographic method was implemented and validated for the simultaneous determination of antimicrobials proposed for the treatment of mycetoma: three fluoroquinolones: ciprofloxacin, moxifloxacin and sparfloxacin; two oxazolidinones: DA-7157 (DA2; torezolid) and its prodrug DA-7218 (DA1). Separation of analytes was achieved on an Atlantis dC18 column (150 × 4.6 mm i.d., 5 µm particle size) with a mobile phase composed of acetonitrile and trifluoroacetic acid 0.1% (v/v) using a gradient program. Total running time was 30 min. Quantification of sparfloxacin was carried out using a DAD at 278 nm; the oxazolidinones DA1 and DA2 and the quinolones ciprofloxacin and moxifloxacin were analyzed by fluorescence with an excitation wavelength of 292 nm and an emission wavelength of 525 nm. Intraday precision was in the range of 3.2 and 14.1%. Linearity range was from 0.3 to 10 µg/mL for sparfloxacin using DAD detector, and from 0.2 to 10 µg/mL for ciprofloxacin, 0.3 to 10 µg/mL forDA2, 0.4 to 10 µg/mL for DA1 and 0.04 to 10 µg/mL for moxifloxacin with fluorescence detector. Acetonitrile was used to precipitate proteins from plasma. Recoveries at low, medium and high concentration were between 80 and 120%. Limits of quantification were between 0.04 and 0.4 µg/mL in plasma. The method can be applied for individual or simultaneous determination of the antimicrobials in plasma.
- 3 March 2014
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 52 (10) , 1281-1287
Open AccessHPLC Method for the Simultaneous Analysis of Fluoroquinolones and Oxazolidinones in Plasma
A chromatographic method was implemented and validated for the simultaneous determination of antimicrobials proposed for the treatment of mycetoma: three fluoroquinolones: ciprofloxacin, moxifloxacin and sparfloxacin; two oxazolidinones: DA-7157 (DA2; torezolid) and its prodrug DA-7218 (DA1). Separation of analytes was achieved on an Atlantis dC18 column (150 × 4.6 mm i.d., 5 µm particle size) with a mobile phase composed of acetonitrile and trifluoroacetic acid 0.1% (v/v) using a gradient program. Total running time was 30 min. Quantification of sparfloxacin was carried out using a DAD at 278 nm; the oxazolidinones DA1 and DA2 and the quinolones ciprofloxacin and moxifloxacin were analyzed by fluorescence with an excitation wavelength of 292 nm and an emission wavelength of 525 nm. Intraday precision was in the range of 3.2 and 14.1%. Linearity range was from 0.3 to 10 µg/mL for sparfloxacin using DAD detector, and from 0.2 to 10 µg/mL for ciprofloxacin, 0.3 to 10 µg/mL forDA2, 0.4 to 10 µg/mL for DA1 and 0.04 to 10 µg/mL for moxifloxacin with fluorescence detector. Acetonitrile was used to precipitate proteins from plasma. Recoveries at low, medium and high concentration were between 80 and 120%. Limits of quantification were between 0.04 and 0.4 µg/mL in plasma. The method can be applied for individual or simultaneous determination of the antimicrobials in plasma.
- Open Access
- 1 January 2014
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 13 (1) , 13
Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages
Due to the emergency of multidrug-resistant strains of Mycobacterium tuberculosis, is necessary the evaluation of new compounds.
- 1 January 2014
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 13 (1) , 13
Open AccessIntracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages
Due to the emergency of multidrug-resistant strains of Mycobacterium tuberculosis, is necessary the evaluation of new compounds.
- 1 January 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (1) , 295-297
Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice
The efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis was evaluated by applying 25 mg of each drug/kg subcutaneously every 8 h in BALB/c mice infected with N. brasiliensis . A statistically significant difference was observed only with moxifloxacin. A moxifloxacin-trimethoprim-sulfamethoxazole combination was as active as when each compound was used alone.
- 1 January 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (1) , 295-297
Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice
The efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis was evaluated by applying 25 mg of each drug/kg subcutaneously every 8 h in BALB/c mice infected with N. brasiliensis . A statistically significant difference was observed only with moxifloxacin. A moxifloxacin-trimethoprim-sulfamethoxazole combination was as active as when each compound was used alone.
- Open Access
- 10 September 2008
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 2 (9) , e289
Therapeutic Effect of a Novel Oxazolidinone, DA-7867, in BALB/c Mice Infected with Nocardia brasiliensis
Mycetoma is a chronic infectious disease of tropical and subtropical countries. It is produced by true fungi and actinobacteria. In México, Nocardia brasiliensis is the main causative agent of mycetoma, producing about 86% of the cases; the gold standard for the therapy of mycetoma by N. brasiliensis is the use of sulfonamides which give a 70% cure rate. The addition of amikacin to this regime increases to 95% the cure rate; however, the patients have to be monitored for creatinine clearance and audiometry studies because of the potential development of side effects. Because of that it is important to search for new active compounds. In the present work, we evaluated the in vivo effect of DA-7867, an experimental oxazolidinone, on the development of experimental mycetomas by N. brasiliensis in BALB/c mice. In order to determine the optimal dose utilized to apply to the animals, we first determined by HPLC the plasma levels using several concentrations of the compounds. Based on these results, we used 10 and 25 mg/kg subcutaneously every 24 hr; DA-7867 was also supplied in the drinking water at a calculated dose of 25 mg/kg. As a control we utilized linezolid at 25 mg/kg, a compound active in murine and human infections, three times a day. The mice were infected in the right footpad with a young culture of N. brasiliensis HUJEG-1, and one week later we started the application of the antimicrobials for six more weeks. After that we compared the development of lesions in the groups injected with saline solution or with the antimicrobials; the results were analyzed by the variance ANOVA test. DA-7867 was able to reduce the production of lesions at 25 mg/kg, when given either subcutaneously or in the drinking water. The experimental oxazolidinone DA-7867 is active in vivo against N. brasiliensis, which opens the possibility of using this drug once it is accepted for human application. Since oxazolidinones seem to be active against a wide spectrum of actinobacteria, it is possible they could be used in human cases of mycetoma by other actinomycetales, such as Streptomyces somaliensis, highly prevalent in Sudan, or Actinomadura madurae and A. pelletieri, which are commonly observed in Africa and India. Actinomycetoma is an infectious disease of tropical and subtropical regions produced by actinobacteria of the genera Nocardia, Streptomyces, and Actinomadura. Therapeutic alternatives are scarce and include trimethoprim-sulfamethoxazole, diaminodiphenylsulfone, amoxicillin-clavulanate, imipenem, and amikacin. Oxazolidinones are a new class of antimicrobials with a completely different cellular target; the first compound in the market, linezolid, was introduced in the year 2000. It is active against many species of Nocardia and other aerobic actinomycetes; however, the long-term application in human subjects produces side effects including peripheral neuropathy and mielossupression. Therefore, it is important to screen other oxazolidinones with higher activity and less toxicity. In the present work, we tested DA-7867, a new oxazolidinone, in an experimental mouse model. The drug is active in vivo and decreases the production of lesions using only one dose a day in contrast to linezolid, which needs to be injected three times a day. Although it was tested on N. brasiliensis, it can possibly be active (once it is accepted for its use in humans) against Actinomadura spp and Streptomyces spp, which are frequently found in places of Africa and India where actinomycetoma is also an important consult in dermatology.
- 10 September 2008
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 2 (9) , e289
Open AccessTherapeutic Effect of a Novel Oxazolidinone, DA-7867, in BALB/c Mice Infected with Nocardia brasiliensis
Mycetoma is a chronic infectious disease of tropical and subtropical countries. It is produced by true fungi and actinobacteria. In México, Nocardia brasiliensis is the main causative agent of mycetoma, producing about 86% of the cases; the gold standard for the therapy of mycetoma by N. brasiliensis is the use of sulfonamides which give a 70% cure rate. The addition of amikacin to this regime increases to 95% the cure rate; however, the patients have to be monitored for creatinine clearance and audiometry studies because of the potential development of side effects. Because of that it is important to search for new active compounds. In the present work, we evaluated the in vivo effect of DA-7867, an experimental oxazolidinone, on the development of experimental mycetomas by N. brasiliensis in BALB/c mice. In order to determine the optimal dose utilized to apply to the animals, we first determined by HPLC the plasma levels using several concentrations of the compounds. Based on these results, we used 10 and 25 mg/kg subcutaneously every 24 hr; DA-7867 was also supplied in the drinking water at a calculated dose of 25 mg/kg. As a control we utilized linezolid at 25 mg/kg, a compound active in murine and human infections, three times a day. The mice were infected in the right footpad with a young culture of N. brasiliensis HUJEG-1, and one week later we started the application of the antimicrobials for six more weeks. After that we compared the development of lesions in the groups injected with saline solution or with the antimicrobials; the results were analyzed by the variance ANOVA test. DA-7867 was able to reduce the production of lesions at 25 mg/kg, when given either subcutaneously or in the drinking water. The experimental oxazolidinone DA-7867 is active in vivo against N. brasiliensis, which opens the possibility of using this drug once it is accepted for human application. Since oxazolidinones seem to be active against a wide spectrum of actinobacteria, it is possible they could be used in human cases of mycetoma by other actinomycetales, such as Streptomyces somaliensis, highly prevalent in Sudan, or Actinomadura madurae and A. pelletieri, which are commonly observed in Africa and India. Actinomycetoma is an infectious disease of tropical and subtropical regions produced by actinobacteria of the genera Nocardia, Streptomyces, and Actinomadura. Therapeutic alternatives are scarce and include trimethoprim-sulfamethoxazole, diaminodiphenylsulfone, amoxicillin-clavulanate, imipenem, and amikacin. Oxazolidinones are a new class of antimicrobials with a completely different cellular target; the first compound in the market, linezolid, was introduced in the year 2000. It is active against many species of Nocardia and other aerobic actinomycetes; however, the long-term application in human subjects produces side effects including peripheral neuropathy and mielossupression. Therefore, it is important to screen other oxazolidinones with higher activity and less toxicity. In the present work, we tested DA-7867, a new oxazolidinone, in an experimental mouse model. The drug is active in vivo and decreases the production of lesions using only one dose a day in contrast to linezolid, which needs to be injected three times a day. Although it was tested on N. brasiliensis, it can possibly be active (once it is accepted for its use in humans) against Actinomadura spp and Streptomyces spp, which are frequently found in places of Africa and India where actinomycetoma is also an important consult in dermatology.
- 1 April 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4) , 1549-1550
In Vivo Therapeutic Effect of Gatifloxacin on BALB/c Mice Infected with Nocardia brasiliensis
In the present work, we evaluated the effect of gatifloxacin on the evolution of experimental murine infection with Nocardia brasiliensis using linezolid as a control. Gatifloxacin was injected subcutaneously at 100 mg/kg body weight every 8 h for 4 weeks. This compound was equally as efficient as linezolid in reducing the production of lesions.
- 1 April 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4) , 1549-1550
In Vivo Therapeutic Effect of Gatifloxacin on BALB/c Mice Infected with Nocardia brasiliensis
In the present work, we evaluated the effect of gatifloxacin on the evolution of experimental murine infection with Nocardia brasiliensis using linezolid as a control. Gatifloxacin was injected subcutaneously at 100 mg/kg body weight every 8 h for 4 weeks. This compound was equally as efficient as linezolid in reducing the production of lesions.